• AG-120 (Ivosidenib): Precision Workflows for Mutant IDH1 AML

  2026-06-05

  AG-120 (Ivosidenib) empowers AML researchers to achieve rapid, reproducible 2-hydroxyglutarate reduction and restoration of myeloid differentiation in vitro and ex vivo. This guide translates cutting-edge metabolic rewiring insights into actionable protocols and troubleshooting strategies, ensuring robust data and experimental confidence.

• Technical Guide: Annexin V-FITC/PI Apoptosis Assay Kit (K200

  2026-06-05

  The Annexin V-FITC/PI Apoptosis Assay Kit offers a practical workflow for discriminating viable, early apoptotic, and late apoptotic or necrotic cells via dual fluorescence staining. It is intended for research applications requiring rapid, reproducible apoptosis detection, but is unsuitable for diagnostic or clinical use due to its intended scope and regulatory status.

• Hyperforin Activates Dlat-Trpv3 Pathway to Boost Adipose The

  2026-06-04

  This study uncovers how hyperforin enhances adipose thermogenesis via the Dlat-Trpv3-Ca2+-AMPK axis, establishing a non-canonical, effective anti-obesity mechanism with favorable pharmacokinetics and minimal cardiac risk. These findings open new avenues for obesity therapy beyond traditional β3-adrenergic receptor targeting.

• Dual SMAD and Wnt Inhibition Enables Efficient iPSC-RGC Diff

  2026-06-04

  The referenced study establishes a robust, chemically defined protocol using dual SMAD and Wnt pathway inhibition to efficiently and reproducibly differentiate human induced pluripotent stem cells into retinal ganglion cells (RGCs) with over 80% purity. This methodological advancement addresses longstanding challenges in uniform RGC generation, supporting more reliable disease modeling and therapeutic discovery in glaucoma and neurodegenerative research.

• PPT1-ZDHHC7 Regulation of SPRY4 Palmitoylation in Cisplatin-

  2026-06-03

  This study uncovers how dynamic palmitoylation of SPRY4, regulated by ZDHHC7 and PPT1, drives cisplatin resistance in osteosarcoma. Targeting PPT1 with GNS561 restores cisplatin sensitivity in resistant cells, offering a novel therapeutic approach.

• Dual-Action p38α MAPK Inhibitors: Conformation and Dephospho

  2026-06-03

  The reference study reveals that certain p38α MAP kinase inhibitors not only block kinase activity but also promote dephosphorylation by stabilizing specific inactive conformations. These findings highlight a dual-action mechanism that may inform the design of more potent and specific inhibitors for inflammatory disease research.

• Structure-Based Discovery of NSP15 Inhibitors in SARS-CoV-2

  2026-06-02

  The referenced study identifies thymopentin and oleuropein as potent inhibitors of the SARS-CoV-2 NSP15 endoribonuclease using structure-based virtual screening and molecular dynamics. These findings highlight NSP15 as a viable antiviral target and provide a foundation for rational drug development against COVID-19.

• Dual-Action Inhibition and Dephosphorylation of p38α MAPK

  2026-06-02

  The reference study uncovers how select kinase inhibitors, including those targeting p38α MAP kinase, not only block enzymatic activity but also accelerate dephosphorylation by phosphatases. This dual-action mechanism has significant implications for the design of more potent and specific kinase inhibitors, especially in inflammatory disease research.

• BMS-345541: Precision IKK-1/IKK-2 Inhibition for Inflammatio

  2026-06-01

  BMS-345541 (free base) is a highly selective IKK-1/IKK-2 inhibitor, enabling rigorous control of NF-κB pathway activity in both inflammation and cancer research. This article unpacks real-world protocols, advanced applications, and troubleshooting strategies, translating the latest reference breakthroughs into actionable assay design.

• Tamoxifen as a Selective Estrogen Receptor Modulator: Bench

  2026-06-01

  Tamoxifen, a gold-standard selective estrogen receptor modulator, underpins breakthrough workflows in breast cancer research, CreER gene knockout, and kinase inhibition studies. Advanced protocol refinements and troubleshooting tips maximize reproducibility and cross-domain discovery with confidence using APExBIO’s high-purity Tamoxifen.

• Pexmetinib (ARRY-614): Optimizing Cytokine Inhibition Workfl

  2026-05-31

  Pexmetinib (ARRY-614) stands out as a dual p38 MAPK and Tie2 inhibitor, uniquely enabling precise, reproducible control of cytokine synthesis in inflammation and myelodysplastic syndromes assays. Leverage its robust inhibition profile, structure-driven insights, and workflow-specific troubleshooting to maximize data reliability and translational relevance.

• EdU Imaging Kits (Cy3): Precision S-Phase DNA Synthesis Dete

  2026-05-30

  EdU Imaging Kits (Cy3) deliver denaturation-free, high-sensitivity cell proliferation detection using robust click chemistry. Optimized for both fluorescence microscopy and flow cytometry, these kits enable reproducible measurement of S-phase DNA synthesis—outperforming traditional BrdU assays in sensitivity, workflow simplicity, and preservation of cell morphology.

• Naloxone Hydrochloride: Beyond Antagonism in Translational R

  2026-05-29

  Naloxone hydrochloride is widely known as an opioid receptor antagonist, but emerging evidence highlights its nuanced roles in neural stem cell proliferation and immune modulation. This article synthesizes mechanistic insights, strategic guidance, and benchmarking practices to empower translational researchers. We explore the biological rationale, experimental best practices, and competitive landscape, contextualizing APExBIO’s high-purity Naloxone (hydrochloride) as an indispensable tool for cutting-edge neurobiology and immunology investigations.

• Strategic Apoptosis Detection: Shaping Immune Evasion Resear

  2026-05-29

  This article explores how mechanistic insights into glyco-immune checkpoints, specifically the PSA-CD56/Siglec-7 axis in clear cell renal cell carcinoma (ccRCC), intersect with advanced apoptosis detection technologies. By highlighting the translational potential of the APExBIO Annexin V-APC/7-AAD Apoptosis Kit, it provides actionable guidance for researchers aiming to dissect tumor immune escape and optimize therapeutic strategies.

• KPT-330 (Selinexor): CRM1 Inhibitor for Cancer Research

  2026-05-28

  KPT-330 (Selinexor) is a selective, orally bioavailable CRM1 inhibitor that induces apoptosis and cell cycle arrest in diverse cancer models. Its efficacy in tumor growth inhibition and synergy with platinum-based chemotherapy are supported by preclinical and translational studies. APExBIO supplies KPT-330 (SKU: B1464) for advanced oncology research.

16302 records 1/1087 page Next 12345 下5页 Last page